1. de Souza NJ, Dohadwalla AN, Reden J. Forskolin: a labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev . 1983;3:201-219. PubMed
2. de Souza NJ. Industrial development of traditional drugs: the forskolin example. A mini-review. J Ethnopharmacol . 1993;38:177-180. PubMed
3. Bhat SV, et al. Structures and stereochemistry of new labdane diterpenoids from Coleus forskohlii Briq. Tetrahedron Lett . 1977;1669.
4. Paulus EF. Molecular and crystal structure of forskolin. Z Kristallogr . 1980;152:239.
5. Paulus EF. Molecular and crystal structure of 1-benzyl-7-desacetyl-7-bromoisobutyryl-forskolin. Absolute configuration of forskolin. Z Kristallogr . 1980;153:43.
6. Roy R, et al. Minor diterpenes from Coleus forskohlii . Phytochemistry . 1993;34:1577.
7. Khandelwal Y, et al. Isolation, structure elucidation, and synthesis of 1-deoxyforskolin. Tetrahedron . 1989;45:763.
8. Tandon JS, et al. Epi-deoxycoleonol, a new antihypertensive labdane diterpenoid from Coleus forskohlii. Bioorg Med Chem Lett . 1992;2:249.
9. Shah VC, D'Sa AS, de Souza NJ. Chonemorphine, stigmasterol, and ecdysterone: steroids isolated through bioassay-directed plant screening programs. Steroids . 1989;53:559-565. PubMed
10. Inamdar PK, Dornauer H, de Souza NJ. GLC method for assay of forskolin, a novel positive inotropic and blood pressure-lowering agent. J Pharm Sci . 1980;69:1449-1451. PubMed
11. Inamdar PK, et al. Quantitative determination of forskolin by TLC and HPLC. Planta Med . 1984;50:30. PubMed
12. Vishwakarma RA, et al. Variation in forskolin content in the roots of Coleus forskohlii . Planta Med . 1988;54:471. PubMed
13. Yanagihara H, et al. Immunoaffinity column chromatography against forskolin using an anti-forskolin monoclonal antibody and its application. Anal Chim Acta . 1996;335:63.
14. Yanagihara H, Sakata R, Shoyama Y, Murakami H. Rapid analysis of small samples containing forskolin using monoclonal antibodies. Planta Med . 1996;62:169-172. PubMed
15. Prakash O, et al. Carbon-13 and proton two-dimensional NMR study of diterpenoids of Coleus forskohlii. Magn Reson Chem . 1988;26:117.
16. Demetzos C, Kolocouris A, Anastasaki T. A simple and rapid method for the differentiation of C-13 manoyl oxide epimers in biologically important samples using GC-MS analysis supported with NMR spectroscopy and computational chemistry results. Bioorg Med Chem Lett . 2002;12:3605-3609. PubMed
17. Mersinger R, Dornauer H, Reinhard E. Formation of forskolin by suspension cultures of Coleus forskohlii . Planta Med . 1988;54:200-204. PubMed
18. Mukherjee S, Ghosh B, Jha S. Establishment of forskolin yielding transformed cell suspension cultures of Coleus forskohlii as controlled by different factors. J Biotechnol . 2000;76:73-81. PubMed
19. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A . 1981;78:3363-3367. PubMed
20. Iwatsubo K, Tsunematsu T, Ishikawa Y. Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy. Expert Opin Ther Targets . 2003;7:441-451. PubMed
21. Sutkowski EM, Robbin JD, Tang WJ, Seamon KB. Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin. Mol Pharmacol . 1996;50:299-305. PubMed
22. Zhang G, Liu Y, Ruoho AE, Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature . 1997;386:247-253. PubMed
23. Onda T, Hashimoto Y, Nagai M, et al. Type-specific regulation of adenylyl cyclase. J Biol Chem . 2001;276:47785-47793. PubMed
24. Toya Y, Schwencke C, Ishikawa Y. Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. J Mol Cell Cardiol . 1998;30:97-108. PubMed
25. Kashiwagi A, Huecksteadt TP, Foley JE. The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. J Biol Chem . 1983;258:13685-13692. PubMed
26. Morris DI, Speicher LA, Ruoho AE, Tew KD, Seamon KB. Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry . 1991;30:8371-8379. PubMed
27. Hoshi T, Garber SS, Aldrich RW. Effect of forskolin on voltage-gated K+ channels is independent of adenylate cyclase activation. Science . 1988;240:1652-1655. PubMed
28. Heuschneider G, Schwartz RD. cAMP and forskolin decrease gamma-aminobutyric acid-gated chloride flux in rat brain synaptoneurosomes. Proc Natl Acad Sci U S A . 1989;86:2938-2942. PubMed
29. Albuquerque EX, Deshpande SS, Aracava Y, Alkondon M, Daly JW. A possible involvement of cyclic AMP in the expression of desensitization of the nicotinic acetylcholine receptor. A study with forskolin and its analogs. FEBS Lett . 1986;199:113-120. PubMed
30. Wagoner PK, Pallotta BS. Modulation of acetylcholine receptor desensitization by forskolin is independent of cAMP. Science . 1988;240:1655-1657. PubMed
31. Dubey MP, Srimal RC, Nityanand S, Dhawan BN. Pharmacological studies on coleonol, a hypotensive diterpene from Coleus forskohlii . J Ethnopharmacol . 1981;3:1-13. PubMed
32. Seamon KB, Vaillancourt R, Edwards M, Daly JW. Binding of [3 H]-forskolin to rat brain membranes. Proc Natl Acad Sci U S A . 1984;81:5081-5085. PubMed
33. Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest . 1984;74:212-223. PubMed
34. Siegl AM, Daly JW, Smith JB. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol . 1982;21:680-687. PubMed
35. Adnot S, Desmier M, Ferry N, Hanoune J, Sevenet T. Forskolin (a powerful inhibitor of human platelet aggregation). Biochem Pharmacol . 1982;31:4071-4074. PubMed
36. Wysham DG, Brotherton AF, Heistad DD. Effects of forskolin on cerebral blood flow: implications for a role of adenylate cyclase. Stroke . 1986;17:1299-1303. PubMed
37. Kreutner W, Chapman RW, Gulbenkian A, Tozzi S. Bronchodilator and antiallergy activity of forskolin. Eur J Pharmacol . 1985;111:1-8. PubMed
38. Marone G, Columbo M, Triggiani M, Cirillo R, Genovese A, Formisano S. Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin. Biochem Pharmacol . 1987;36:13-20. PubMed
39. Hersey SJ, Owirodu A, Miller M. Forskolin stimulation of acid and pepsinogen secretion by gastric glands. Biochim Biophys Acta . 1983;755:293-299. PubMed
40. Bauer K, Dietersdorder F, Sertl K, Kaik B, Kaik G. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther . 1993;53:76-83. PubMed
41. Lee PY, Podos SM, Serle JB, Camras CB, Severin CH. Intraocular pressure effects of multiple doses of drugs applied to glaucomatous monkey eyes. Arch Ophthalmol . 1987;105:249-252. PubMed
42. Brubaker RF, Carlson KH, Kullerstrand LJ, McLaren JW. Topical forskolin (colforsin) and aqueous flow in humans. Arch Ophthalmol . 1987;105:637-641. PubMed
43. Okuda H, Morimoto C, Tsujita T. Relationship between cyclic AMP production and lipolysis induced by forskolin in rat fat cells. J Lipid Res . 1992;33:225-231. PubMed
44. Majeed M, et al. Method of preparing a forskolin composition from forskolin extract and use of forskolin for promoting lean body mass and treating mood disorders. US patent 5804596. 1997.
45. Maeda H, Ozawa H, Saito T, Irie T, Takahata N. Potential antidepressant properties of forskolin and a novel water-soluble forskolin (NKH477) in the forced swimming test. Life Sci . 1997;61:2435-2442. PubMed
46. Drewes SE, George J, Khan F. Recent findings on natural products with erectile-dysfunction activity. Phytochemistry . 2003;62:1019-1025. PubMed
47. Mulhall JP, Duller M, Traish AM, et al. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol . 1997;158:1752-1758. PubMed